Insider Buying: FocalTherics (NASDAQ:FOCL) Director Purchases 10,000 Shares of Stock

FocalTherics (NASDAQ:FOCL) Director Joshua Levine purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the purchase, the director owned 45,000 shares in the company, valued at approximately $213,750. The trade was a 28.57% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

FocalTherics Stock Performance

FocalTherics stock opened at $4.76 on Monday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40. The firm has a market cap of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. The stock’s fifty day simple moving average is $5.39.

FocalTherics (NASDAQ:FOCL) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million for the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. On average, research analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. Mizuho set a $15.00 price target on FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. Finally, Piper Sandler reissued a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a report on Friday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.75.

Institutional Trading of FocalTherics

Several institutional investors have recently modified their holdings of the business. SmartHarvest Portfolios LLC bought a new position in FocalTherics during the 1st quarter worth $38,000. Lido Advisors LLC acquired a new position in FocalTherics during the 1st quarter worth about $40,000. Kovack Advisors Inc. bought a new stake in shares of FocalTherics in the 4th quarter valued at about $53,000. Leonteq Securities AG acquired a new stake in shares of FocalTherics in the fourth quarter valued at about $313,000. Finally, Flax Pond Capital LLC acquired a new stake in shares of FocalTherics in the fourth quarter valued at about $2,623,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.